Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that its common stock has been approved for trading on...
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) ("Immune" or the "Company") announced today its financial results for the ...
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that it has appointed Erik Penser Bankaktiebolag as a...
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Tomer Adar, M.D. at the Digestive Diseases...
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP), announced today that Rene Lerer, M.D., Executive Chairman of Magellan...
Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr. Daniel G. Teper, Company Chairman and CEO, will...
Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: IMNP, formerly EPCTD) announced today that effective September 23, 2013...
Immune Pharmaceuticals Inc. (NASDAQ OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) today announced it will be featured as a presenting company at the ...
Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) ("Immune" or the "Company") announced today that it has executed...
Immune Pharmaceuticals Inc. (Nasdaq OMX Stockholm Exchange: IMNP and OTCQX: EPCTD) (the "Company") announced today the completion of the merger of...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.